Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB (HR1)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01392911 |
Recruitment Status :
Completed
First Posted : July 13, 2011
Last Update Posted : November 26, 2018
|
Sponsor:
Radboud University Medical Center
Collaborators:
European and Developing Countries Clinical Trials Partnership (EDCTP)
Department of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands.
University Centre for Chronic Diseases Dekkerswald, Groesbeek, NL
Information provided by (Responsible Party):
Radboud University Medical Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | July 2018 |
Actual Study Completion Date : | November 2018 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):